Brain Cancer Clinical Trials in Chicago

Showing 161-180 of 190 trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

NCT00326664

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic Astrocytoma+18 more

National Cancer Institute (NCI)55 participantsStarted Mar 2006

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +8 more locations

COMPLETEDPhase 22.2 miles

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

NCT01462695

This phase II trial studies how well sunitinib malate works in treating younger patients with recurrent, refractory, or progressive malignant glioma or ependymoma. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Childhood Cerebellar Anaplastic AstrocytomaChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral Astrocytoma+8 more

National Cancer Institute (NCI)30 participantsStarted Jan 2012

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Little Rock, Arkansas, United States +93 more locations

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Brain Cancer Trials in Other Cities

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Tolerability Study of Xerecept® in Pediatric Patients

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

AMG 595 First-in-Human in Recurrent Gliomas

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

MK-2206 for Recurrent Malignant Glioma

Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme

Other Conditions in Chicago